The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
Zuranolone for the Treatment of Postpartum Depression
Abstract
OBJECTIVE: receptors and neuroactive steroid, as an oral, once-daily, 14-day treatment course for patients with severe PPD. METHODS: In this double-blind phase 3 trial, women with severe PPD were randomized in a 1:1 ratio to receive zuranolone 50 mg/day or placebo for 14 days. The primary endpoint was change from baseline in total score on the 17-item Hamilton Depression Rating Scale (HAM-D) at day 15; key secondary endpoints were change from baseline in HAM-D score at days 3, 28, and 45 and change from baseline in Clinical Global Impressions severity (CGI-S) score at day 15. Adverse events were monitored. RESULTS: Among 196 patients randomized (zuranolone, N=98; placebo, N=98), 170 (86.7%) completed the 45-day study. Treatment with zuranolone compared with placebo resulted in statistically significant improvement in depressive symptoms at day 15 (least squares mean [LSM] change from baseline in HAM-D score, -15.6 vs. -11.6; LSM difference, -4.0, 95% CI=-6.3, -1.7); significant improvement in depressive symptoms was also reported at days 3, 28, and 45. CGI-S score at day 15 significantly improved with zuranolone compared with placebo. The most common adverse events (≥10%) with zuranolone were somnolence, dizziness, and sedation. No loss of consciousness, withdrawal symptoms, or increased suicidal ideation or behavior were observed. CONCLUSIONS: In this trial, zuranolone demonstrated significant improvements in depressive symptoms and was generally well tolerated, supporting the potential of zuranolone as a novel, rapid-acting oral treatment for PPD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another very recent phase III trial compared Zuranolone versus placebo in 196 patients, showing significant positive results in improving depressive symptoms on patients with PPD on days 3, 15, 28, and 45 [190].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [190]
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Wang, P. S., Lane, M., Olfson, M., Pincus, H. A., Wells, K. B., & Kessler, R. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.629 · Cited by 2,695
Meltzer-Brody, S., Colquhoun, H., Riesenberg, R., Epperson, C. N., Deligiannidis, K. M., Rubinow, D. R., Li, H., Sankoh, A. J., Clemson, C., Schacterle, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31551-4 · Cited by 795
Self-citationMapping global prevalence of depression among postpartum women
Wang, Z., Liu, J., Shuai, H., Cai, Z., Fu, X., Liu, Y., Xiao, X., Zhang, W., Krabbendam, E., Liu, S., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01663-6 · Cited by 734
SSRI Antidepressant Medications: Adverse Effects and Tolerability
Ferguson, J. M. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0105 · Cited by 669
Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial.
Kanes, S., Colquhoun, H., Gunduz-Bruce, H., Raines, S., Arnold, R., Schacterle, A., Doherty, J., Epperson, C. N., Deligiannidis, K. M., Riesenberg, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31264-3 · Cited by 479
Self-citationPathophysiological mechanisms implicated in postpartum depression
Payne, J. L., & Maguire, J. (2019) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2018.12.001 · Cited by 459
GABAAR Plasticity during Pregnancy: Relevance to Postpartum Depression
Maguire, J., & Mody, I. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.019 · Cited by 437
Bauman, B. L., Ko, J. Y., Cox, S., D’Angelo, M., Warner, L., Folger, S., Tevendale, H. D., Coy, K. C., Harrison, L., & Barfield, W. D. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6919a2 · Cited by 399
Research works printed but not linked: 2
- 2019, Zulresso (Brexanolone) injection: full prescribing information
- Brown JV, 2021, Cochrane Database Syst Rev, 2, CD013560
Cited by
Neuroanatomical changes observed over the course of a human pregnancy
Pritschet, L., Taylor, C. M., Cossio, D. M., Faskowitz, J., Santander, T., Handwerker, D. A., Grotzinger, H., Layher, E., Chrastil, E. R., & Jacobs, E. G. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01741-0 · Cited by 222
“One in five women experiences perinatal depression 45 and while the first FDA-approved treatment is now available 46 , early detection remains elusive.”
Cutler, A. J., Mattingly, G. W., & Maletic, V. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02514-2 · Cited by 190
Luo, W., Liu, Y., Qin, H., Zhao, Z., Wang, S., He, W., Tang, S., & Peng, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116838 · Cited by 113
Patterson, R., Balan, I. S., Morrow, A. L., & Meltzer-Brody, S. E. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01721-1 · Cited by 95
“The phase 2 and 3 double blind studies of zuranolone have demonstrated ef fi cacy and safety of zuranolone vs placebo in the outpatient treatment of adult women with PPD [55, 56].”
BackgroundMethodSelf-citationKhamidullina, Z., Marat, A., Muratbekova, S., Mustapayeva, N. M., Chingayeva, G. N., Shepetov, A. M., Ibatova, S. S., Terzic, M., & Aimagambetova, G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14072418 · Cited by 63
“A recent study also reported that zuranolone was well tolerated by patients and demonstrated significant improvements in depressive symptoms [115].”
Metadata
- Authors
- Deligiannidis, K. M., Meltzer-Brody, S., Maximos, B., Peeper, E. Q., Freeman, M., Lasser, R., Bullock, A., Kotecha, M., Li, S., Forrestal, F., Rana, N., Garcia, M., Leclair, B., & Doherty, J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Venue
- American Journal of Psychiatry
- Published
- 2023-09-01
- Volume
- 180
- Issue
- 9
- Pages
- 668-675
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W4385264693
- Cited by
- 192
- References
- 33
- Citations by year
- 2026: 48 · 2025: 56 · 2024: 70 · 2023: 18
- FWCI
- 48.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Personality Disorders and Psychopathology
- Keywords
- zuranolone, postpartum depression, neurosteroids, GABA-A receptor modulation, rapid-acting antidepressants, antidepressant tolerability, sleepiness
- MeSH terms
- Double-Blind Method, Female, Humans, Pregnancy, Pregnanes, Pregnanolone, Pyrazoles, Treatment Outcome, Depression, Postpartum
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Zuranolone for the Treatment of Postpartum Depression. https://app.cochat.ai/papers/10.1176/appi.ajp.20220785
- The paper
- Deligiannidis, K. M., Meltzer-Brody, S., Maximos, B., Peeper, E. Q., Freeman, M., Lasser, R., Bullock, A., Kotecha, M., Li, S., Forrestal, F., Rana, N., Garcia, M., Leclair, B., & Doherty, J. (2023). Zuranolone for the Treatment of Postpartum Depression. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.20220785
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.